AOA Dx Announced As Finalist For The Eddies, Massachusetts Innovation...
AOA Dx is proud to announce the company has been chosen as a finalist for Massachusetts Innovation Network’ signature innovation competition, The Eddies. Finalists will have the chance to participate...
View ArticleAOA Dx was selected for MassChallenge’s 2022 US Early-Stage Cohort
AOA Dx is excited to share that the company has been selected to participate in the MassChallenge 2022 accelerator program, joining more than 200 startups. AOA Dx was one of over 1,000 other startup...
View ArticleClik here to view.
AOA Dx Closes $7 million Funding Round to Bring the First Accurate Early...
AOA Dx is proud to announce that they have closed both of their seed rounds totaling a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent...
View ArticleClik here to view.
AOA Dx Co-Founders Oriana Papin-Zoghbi and Anna Jeter Named to Inc.’s 2022...
AOA Dx is proud to announce that co-founders Oriana Papin-Zoghbi and Anna Jeter have been named to Inc.’s 2022 Female Founders 100 List. Inc.’s fifth annual Female Founders 100 list honors a bold...
View ArticleMassachusetts Innovation Network Announces AOA Dx as the Award Recipient of...
Boston, MA: AOA Dx is proud to announce the company has won the Life Science award, the People’s Choice Award, and the Robert J. Crowley award at the Massachusetts Innovation Network’ signature...
View ArticleClik here to view.
AOA Dx Announces Initial Validation of Novel Tumor Gangliosides as Promising...
Boston, MA: AOA Dx announces initial validation of GD2 and GD3 tumor marker gangliosides as novel diagnostic markers for early detection of ovarian cancer. AOA Dx results will be presented at the...
View ArticleClik here to view.
AOA Dx Announces First Patient Enrolled in OVERT Clinical Study Evaluating...
Boston, MA: AOA Dx, a diagnostic company focused on early detection of cancer, today announced that the first patient has been enrolled in their OVERT (Ovarian Cancer Early Detection Research) clinical...
View ArticleAOA Dx’s First Peer Reviewed Study Accepted for Publication in Prestigious...
AOA Dx, a biotech company developing a new frontier in early-stage cancer detection through its work in glycolipids, is proud to announce the company’s first published peer reviewed clinical study. The...
View ArticleCEO and Co-Founder Oriana Papin-Zoghbi selected for Bloomberg New Economy...
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the Bloomberg New Economy Catalysts and will represent the women's health industry at the Bloomberg New Economy...
View ArticleClik here to view.
AOA Dx secures $17 Million to revolutionize the diagnosis of ovarian cancer...
New York, NY: AOA Dx, a startup biotech company developing the first early detection test for ovarian cancer, is announcing an oversubscribed $17 million round led by Good Growth Capital with...
View Article
